RU2736312C2 - Белки, специфичные в отношении cd137 - Google Patents

Белки, специфичные в отношении cd137 Download PDF

Info

Publication number
RU2736312C2
RU2736312C2 RU2017135599A RU2017135599A RU2736312C2 RU 2736312 C2 RU2736312 C2 RU 2736312C2 RU 2017135599 A RU2017135599 A RU 2017135599A RU 2017135599 A RU2017135599 A RU 2017135599A RU 2736312 C2 RU2736312 C2 RU 2736312C2
Authority
RU
Russia
Prior art keywords
ser
lys
asp
leu
glu
Prior art date
Application number
RU2017135599A
Other languages
English (en)
Russian (ru)
Other versions
RU2017135599A3 (enExample
RU2017135599A (ru
Inventor
Марлон ХИННЕР
Кристине РОТЕ
Шейн ОЛЬВИЛЛЬ
Андреа АЛЛЕРСДОРФЕР
АЙБА Рачида Сихам БЕЛ
Original Assignee
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ filed Critical ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ
Publication of RU2017135599A publication Critical patent/RU2017135599A/ru
Publication of RU2017135599A3 publication Critical patent/RU2017135599A3/ru
Application granted granted Critical
Publication of RU2736312C2 publication Critical patent/RU2736312C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017135599A 2015-05-04 2016-05-04 Белки, специфичные в отношении cd137 RU2736312C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166184 2015-05-04
EP15166184.0 2015-05-04
PCT/EP2016/059959 WO2016177762A1 (en) 2015-05-04 2016-05-04 Proteins specific for cd137

Publications (3)

Publication Number Publication Date
RU2017135599A RU2017135599A (ru) 2019-06-04
RU2017135599A3 RU2017135599A3 (enExample) 2019-09-27
RU2736312C2 true RU2736312C2 (ru) 2020-11-13

Family

ID=53054879

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017135599A RU2736312C2 (ru) 2015-05-04 2016-05-04 Белки, специфичные в отношении cd137

Country Status (18)

Country Link
US (2) US11261221B2 (enExample)
EP (2) EP4177262A1 (enExample)
JP (3) JP6884708B2 (enExample)
KR (1) KR102734408B1 (enExample)
CN (2) CN107820500B (enExample)
AU (1) AU2016258952C1 (enExample)
CA (1) CA2980839C (enExample)
CL (1) CL2017002767A1 (enExample)
DK (1) DK3292137T3 (enExample)
ES (1) ES2932425T3 (enExample)
IL (1) IL254516B (enExample)
MX (1) MX2017014082A (enExample)
NZ (1) NZ736560A (enExample)
PH (1) PH12017501583B1 (enExample)
RU (1) RU2736312C2 (enExample)
SG (1) SG11201708339QA (enExample)
WO (1) WO2016177762A1 (enExample)
ZA (1) ZA201705960B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
FI3298030T3 (fi) 2015-05-18 2023-02-22 Pieris Pharmaceuticals Gmbh Syöpää ehkäisevä fuusiopolypeptidi
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
SG11201803732PA (en) 2015-11-30 2018-06-28 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN112004535A (zh) 2018-03-26 2020-11-27 4Sc股份公司 用于癌症疗法的包括hdac抑制剂和cd137激动剂的组合
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
AU2019315703A1 (en) * 2018-07-31 2020-12-10 Les Laboratoires Servier Novel fusion protein specific for CD137 and PD-L1
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
US12486330B2 (en) * 2019-02-26 2025-12-02 Pieris Pharmaceuticals Gmbh Fusion proteins specific for CD137 and GPC3
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
EP3952996A1 (en) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
JP2023502876A (ja) 2019-11-04 2023-01-26 ピエリス ファーマシューティカルズ ゲーエムベーハー がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質
CN116249709A (zh) 2020-06-05 2023-06-09 皮里斯制药有限公司 靶向4-1bb的多聚体免疫调节剂
EP4213946A1 (en) 2020-09-18 2023-07-26 Pieris Pharmaceuticals GmbH Biomarker methods and uses
CN117355319A (zh) 2021-03-23 2024-01-05 皮里斯制药有限责任公司 用于癌症治疗的her2/4-1bb双特异性融合蛋白
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
WO2023118497A1 (en) 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156456A1 (en) * 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
RU2012128586A (ru) * 2009-12-07 2014-01-20 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CA2702590A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
CA2808392C (en) * 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
DK2640740T3 (en) 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
CA2905186A1 (en) 2013-03-14 2014-09-18 Daiichi Sankyo Co., Ltd Novel binding proteins for pcsk9
CA2891557A1 (en) * 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
AR103714A1 (es) 2015-02-18 2017-05-31 Sanofi Sa Proteínas específicas para pioverdina y pioquelina
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
FI3298030T3 (fi) * 2015-05-18 2023-02-22 Pieris Pharmaceuticals Gmbh Syöpää ehkäisevä fuusiopolypeptidi
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156456A1 (en) * 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
RU2012128586A (ru) * 2009-12-07 2014-01-20 Пирис Аг МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LYNCH D. H., The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer, IMMUNOLOGICAL REVIEWS, v.222, p.277 - 286. SCHLEHUBER S. et al., Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins", Drug Discov Today, 2005, v.10, n.1, p.23-33. *

Also Published As

Publication number Publication date
US12195503B2 (en) 2025-01-14
EP3292137A1 (en) 2018-03-14
RU2017135599A3 (enExample) 2019-09-27
CL2017002767A1 (es) 2018-07-20
CN107820500A (zh) 2018-03-20
CN107820500B (zh) 2022-03-01
CA2980839A1 (en) 2016-11-10
US11261221B2 (en) 2022-03-01
AU2016258952A1 (en) 2017-11-09
US20220144901A1 (en) 2022-05-12
ES2932425T3 (es) 2023-01-19
IL254516B (en) 2021-10-31
AU2016258952C1 (en) 2020-12-24
KR20170142200A (ko) 2017-12-27
US20180148484A1 (en) 2018-05-31
CA2980839C (en) 2024-09-10
PH12017501583B1 (en) 2023-01-20
MX2017014082A (es) 2018-06-28
JP6884708B2 (ja) 2021-06-09
IL254516A0 (en) 2017-11-30
RU2017135599A (ru) 2019-06-04
JP7477905B2 (ja) 2024-05-02
AU2016258952B2 (en) 2020-08-27
JP2018515084A (ja) 2018-06-14
NZ736560A (en) 2021-12-24
JP2022177231A (ja) 2022-11-30
PH12017501583A1 (en) 2018-02-05
JP7149363B2 (ja) 2022-10-06
WO2016177762A1 (en) 2016-11-10
BR112017020426A2 (en) 2018-06-26
EP3292137B1 (en) 2022-09-07
DK3292137T3 (da) 2022-10-17
ZA201705960B (en) 2023-03-29
HK1249527A1 (en) 2018-11-02
KR102734408B1 (ko) 2024-11-27
JP2021097695A (ja) 2021-07-01
CN114573680A (zh) 2022-06-03
SG11201708339QA (en) 2017-11-29
EP4177262A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
US12195503B2 (en) Proteins specific for CD137
JP7108535B2 (ja) Ｌａｇ－３に特異的な新規タンパク質
JP7225116B2 (ja) Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
WO2018087108A1 (en) Proteins specific for cd137
HK40093181A (en) Proteins specific for cd137
HK1249527B (en) Proteins specific for cd137
BR112017020426B1 (pt) Muteína de lipocalina, uso de uma ou mais muteínas e composição farmacêutica